Medically reviewed by Drugs.com. Last updated on Aug 30, 2018.
Applies to the following strengths: 5 mg; 10 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
Initial dose: 5 mg orally once a day
-May increase to 10 mg orally once a day for additional glycemic control if lower dose has been tolerated
Maximum dose: 10 mg/day
-Correct volume depletion prior to initiating therapy.
-If used in combination with insulin or an insulin secretagogue, a lower dose of insulin or the insulin secretagogue should be considered to reduce the risk of hypoglycemia.
Use: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Renal Dose Adjustments
eGFR 45 mL/min/1.73 m2 or greater: No adjustment recommended
eGFR less than 45 mL/min/1.73 m2: Use is not recommended
eGFR is less than 30 mL/min/1.73 m2: Use is contraindicated
Liver Dose Adjustments
No adjustment recommended; however, for patients with severe hepatic impairment, use caution as the safety and efficacy has not been specifically studied
-Serious hypersensitivity reaction to this drug
-Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), ESRD, or dialysis
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
-Take orally in the morning, with or without food
Missed Dose: If a dose is missed, take it as soon as it is remembered, if it is almost time for the next dose, the missed dose should be skipped; do not take 2 doses at the same time.
-Correct volume depletion prior to initiating treatment
-Not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
-Assess fluid status prior to initiation and monitor for signs and symptoms of volume depletion during therapy
-Obtain baseline renal function and monitor periodically during therapy
-Monitor for signs and symptoms of acute kidney injury
-Monitor for LDL-C per standard of care
-Evaluate for the presence of acidosis, including ketoacidosis in symptomatic patients, even if blood sugar is below 250 mg/dL.
-Patients should be instructed to read the US FDA-approved patient labeling (Medication Guide).
-Patients should understand that this drug will cause the urine to test positive for glucose.
-Patients should be instructed to maintain adequate fluid intake.
-Patients should be instructed to seek medical advice during periods of stress or illness as medical management of diabetes may change.
-Patients should understand that genital mycotic infections, urinary tract infections, and hypersensitivity reactions may occur; patients should be instructed to contact their health care professional.
-Patients should be instructed to seek immediate medical attention for symptoms of tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, especially if they have a fever and are feeling unwell.
-Patients experiencing symptoms of ketoacidosis such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue, or sleepiness should be instructed to seek immediate medical attention.
-Patients should promptly report signs of macroscopic hematuria or other symptoms potentially related to bladder cancer.
-Patients should be instructed to seek prompt medical attention for signs and symptoms of acute kidney injury such as decreased urine, swelling in the legs or feet.
-Patients should be instructed on routine preventative foot care.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about dapagliflozin
- Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- 114 Reviews
- Drug class: SGLT-2 inhibitors
- FDA Alerts (3)
Other brands: Farxiga